Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer

Author:

Boudadi Karim1,Suzman Daniel L.2,Anagnostou Valsamo1,Fu Wei1,Luber Brandon1,Wang Hao1,Niknafs Noushin1,White James R.1,Silberstein John L.3,Sullivan Rana1,Dowling Donna1,Harb Rana1,Nirschl Thomas R.1,Veeneman Brendan A.45,Tomlins Scott A.46,Wang Yipeng7,Jendrisak Adam7,Graf Ryon P.7,Dittamore Ryan7,Carducci Michael A.1,Eisenberger Mario A.1,Haffner Michael C.8,Meeker Alan K.8,Eshleman James R.8,Luo Jun3,Velculescu Victor E.1,Drake Charles G.9,Antonarakis Emmanuel S.13

Affiliation:

1. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

2. Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA

3. Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

4. Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA

5. Present address: Pfizer Inc., Pearl River, NY, USA

6. Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA

7. Epic Sciences Inc., San Diego, CA, USA

8. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

9. Department of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA

Publisher

Impact Journals, LLC

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3